Trials / Not Yet Recruiting
Not Yet RecruitingNCT06415903
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
A Phase I Study to Evaluate the Safety and Tolerance of TQB3117 Tablets in Patients With Advanced Malignant Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is divided into two phases: dose escalation and dose extension. The dosing regimens include a single-dose study and a multiple-dose study. It adopts a single-center, open-label, non-randomized, single-arm clinical trial design, where patients with advanced malignant cancer are selected to orally take TQB3117 tablets. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TQB3117 tablets in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3117 tablets | TQB3117 is a protein inhibitor. |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2025-06-01
- Completion
- 2026-08-01
- First posted
- 2024-05-16
- Last updated
- 2024-05-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06415903. Inclusion in this directory is not an endorsement.